TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00558896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg/day administered through PO (with food) at Days 1, 8, 15, 22 per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg/day administered through PO (with food) at Days 1, 8, 15, 22 per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg/day administered through PO (with food) at Days 1, 8, 15, 22 per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg/day administered through PO (with food) at Days 1, 8, 15, 22 per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg/day administered through PO (with food) at Days 1, 8, 15, 22 per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg/day administered through PO (with food) at Days 1, 8, 15, 22 per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg/day administered through PO (with food) at Days 1, 8, 15, 22 per cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: 2 or 4 mg/day administered through PO at days 1 - 28 or days 1-21 (see Arm description for specific dosing).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: 2 or 4 mg/day administered through PO at days 1 - 28 or days 1-21 (see Arm description for specific dosing).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: 2 or 4 mg/day administered through PO at days 1 - 28 or days 1-21 (see Arm description for specific dosing).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: 2 or 4 mg/day administered through PO at days 1 - 28 or days 1-21 (see Arm description for specific dosing).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: 2 or 4 mg/day administered through PO at days 1 - 28 or days 1-21 (see Arm description for specific dosing).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: 2 or 4 mg/day administered through PO at days 1 - 28 or days 1-21 (see Arm description for specific dosing).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: 2 or 4 mg/day administered through PO at days 1 - 28 or days 1-21 (see Arm description for specific dosing).
Study: NCT00705458

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary Computed Tomography Angiography
Description: 64-detector, retrospectively EKG-gated, computed tomography angiography of the coronary arteries during heart rate control (intravenous metoprolol, when necessary)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stress Nuclear Myocardial Perfusion Imaging
Description: Usually dual-isotope perfusion imaging at rest (201-Thallium) and at stress (99m-Technetium-MIBI). Some patients will have a 2-day MIBI protocol. Gated SPECT and attenuation-correction images will be obtained. Treadmill stress will be performed. If a patient is unable to exercise, adenosine or dobutamine will be given.
Study: NCT00996411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salvinorin A
Description: This is an initial dose ranging study
Study: NCT01367496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC Methylnaltrexone (MNTX)
Description: Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC Methylnaltrexone (MNTX)
Description: Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC Methylnaltrexone (MNTX)
Description: Dose 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Methylnaltrexone (MNTX)
Study: NCT02381938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyles
Description: 6-month intervention to increase physical activity and improve other health related behaviors

Intervention type: OTHER
Group type: OTHER
Intervention: Healthy Finances
Description: 6-month intervention to educate and improve financial health
Study: NCT03611231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 20mg orally BIW. Treatment cycles are repeated every 4 weeks.
Study: NCT01877356

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bilateral spinal anesthesia
Description: prilocaine plain 2% 50 mg

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: unilateral spinal anesthesia
Description: prilocaine 2% hyperbaric 30 mg
Study: NCT01323153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalcetrapib
Description: Oral doses of 600 mg once daily for 20 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral doses of matching placebo to dalcetrapib once daily for 20 weeks
Study: NCT00497978

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: taurine
Description: 6 grams of taurine will be given each day in capsules, starting the day of admission till the sixth postoperative day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: a similar amount of placebo will be given each day in capsules, starting the day of admission till the sixth postoperative day
Study: NCT04721704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin+ Amoxicillin + Omeprazole
Description: In Group A: Amoxicillin AMO + Clarithromycin CLA + Proton pump inhibitor PPI will be given to children

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole +Amoxicillin + Omeprazole
Description: Group B: Amoxicillin AMO+ Metronidazole MET+ Proton pump inhibitor PPI
Study: NCT03068819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIML NK Cell Infusion
Description: -Day 0

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIML NK Cell Infusion
Description: -Day 0

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CD3+ T Cell Product Infusion
Description: -Day -1

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CD3+ T Cell Product Infusion
Description: -Day -1
Study: NCT01500408

Intervention type: DRUG
Group type: OTHER
Intervention: Interferon beta-1a (current approved manufacturing process invloving FBS)
Description: Single dose of 60 mcg given Intramuscularly (IM)

Intervention type: DRUG
Group type: OTHER
Intervention: Interferon beta-1a (current approved manufacturing process invloving FBS)
Description: Single dose of 60 mcg given Intramuscularly (IM)

Intervention type: DRUG
Group type: OTHER
Intervention: Interferon beta-1a (new process, manufactured without FBS)
Description: Single dose of 60 mcg given Intramuscularly (IM)

Intervention type: DRUG
Group type: OTHER
Intervention: Interferon beta-1a (new process, manufactured without FBS)
Description: Single dose of 60 mcg given Intramuscularly (IM)
Study: NCT03219151

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eMAR game
Description: The eMAR simulator videogame affords students a virtual and immersive opportunity to practice medication administration using an eMAR system, in a structured fashion that provides real-time feedback related to best-practices and safety compliance of the medication process

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal pre-work
Description: Participants complete normal education pre-work related to eMAR administration, in advance of simulated return-demonstration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal pre-work
Description: Participants complete normal education pre-work related to eMAR administration, in advance of simulated return-demonstration
Study: NCT02560324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramelteon

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02186847

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Radiation therapy (RT) is given in 2 Gy fractions once daily 5 days per week to a total of 30 fractions and 60 Gy. Photons required; 3-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) permitted. Starts within 14 days of randomization (Chemoradiation arm) or 14 days after metformin starts (Chemoradiation + Metformin arm).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy (RT) is given in 2 Gy fractions once daily 5 days per week to a total of 30 fractions and 60 Gy. Photons required; 3-dimensional conformal radiation therapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) permitted. Starts within 14 days of randomization (Chemoradiation arm) or 14 days after metformin starts (Chemoradiation + Metformin arm).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: 2 AUC (area under the curve) via IV weekly on days 1, 8, 15, 22, 29, and 36 from start of radiation therapy. Two 21 day cycles of 6 AUC via IV starting 28-42 days after the end of radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 2 AUC (area under the curve) via IV weekly on days 1, 8, 15, 22, 29, and 36 from start of radiation therapy. Two 21 day cycles of 6 AUC via IV starting 28-42 days after the end of radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin is taken orally. Dose escalation begins 2 weeks prior to the initiation of chemoradiation. 500 mg twice daily days 1-7 of metformin. 500 mg three times daily days 8-14 of metformin. Three times a day with the following dosage: 500mg in the morning, 1000mg at noon, and 500mg in the evening concurrent with chemoradiation and through consolidation chemotherapy (days 15-126 of metformin),

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 50 mg/m2 via IV weekly on days 1, 8, 15, 22, 29, and 36 from start of radiation therapy. Two 21 day cycles of 200 mg/m2 via IV 28-42 days after the end of radiation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 50 mg/m2 via IV weekly on days 1, 8, 15, 22, 29, and 36 from start of radiation therapy. Two 21 day cycles of 200 mg/m2 via IV 28-42 days after the end of radiation therapy.
Study: NCT01446276

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 500 mg 3 times daily for six month

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo tablet 3 times daily for six month
Study: NCT02134002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disulfiram
Description: Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
Study: NCT02143791

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Burst and Tonic stimulation
Study: NCT03375879

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bandage contact lens
Description: Bandage contact lens
Study: NCT01237249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Velcade

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Revlimid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT02550600

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: iLA activve treatment
Description: iLA activve is aimed at efficient extracorporeal membrane oxygenation with an initial blood flow of ≥2L/min. The length of therapy is at the discretion of the treating physician.~Treating physicians are recommended to use a pre-specified algorithm to optimize the extracorporeal lung assist (choice of cannulas and oxygenator, titration of blood flow and sweep gas flow). Primary/mandatory goals are pO2≥65mmHg, P_peak ≤30cm H2O, TV ≤6ml/kg PBW and pH ≥7.25. Secondary suggested goals are setting the PEEP level within the limits suggested by the ARDSnet low and high PEEP strategy, 35mmHg ≤ pCO2 ≤45mmHg, Delta-pressure (= P_peak - PEEP) ≤15 cm H2O and P_peak ≤25 cm H2O.~iLA activve treatment also requires anticoagulation with un-fractionized heparin (PTT-goal 45s-60s depending on blood flow).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: The controls will be treated according to the recent guideline of the German Sepsis Society and the German Interdisciplinary Association of Intensive Care and Emergency Medicine and good clinical practice including lung-protective ventilation with low tidal volume (LTV), moderate hypercapnia, PEEP according to ARDSnet, adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) and treatment of the underlying disease as applied in the experimental group.~There will be no sham treatment of iLA activve.in the controls. All adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) are also available for the intervention group.
Study: NCT04605380

Intervention type: OTHER
Intervention: Virtual reality online world
Description: Virtual patient with open fracture inside a virtual world

Intervention type: OTHER
Intervention: Virtual reality online world
Description: Virtual patient with open fracture inside a virtual world

Intervention type: OTHER
Intervention: Virtual reality online world
Description: Virtual patient with open fracture inside a virtual world
Study: NCT02678585

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine
Description: 53 patients received intravenous regional lidocaine plus nalbuphine

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine
Description: 53 patients received intravenous regional lidocaine
Study: NCT03336268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POINT
Description: A recovery coach meets patients in the ED after they have been revived from an overdose to offer a range of services including an assessment of high-risk behaviors, Hep C/HIV testing, harm reduction counseling, and treatment referrals with follow-up to either a medication for opioid use disorder (MOUD) provider, detoxification services, or an inpatient treatment setting. Patients are offered a take-home naloxone kit and assistance with Medicaid enrollment. Close collaboration with the local community mental health provider ensures POINT patients have their first assessment for MOUD within 1-2 business days of ED discharge. Also, recovery coaches offer to accompany patients to intake appointments or criminal justice and child welfare meetings as part of the standard care they deliver.
Study: NCT02657577

Intervention type: OTHER
Intervention: There is no intervention
Description: There is no intervention

Intervention type: OTHER
Intervention: There is no intervention
Description: There is no intervention
Study: NCT03184337

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CDC's PreventT2 Program
Description: The PreventT2 program will involve 8 group sessions administered over 3 months. It is a behavioral intervention focused on achieving weight loss by improving nutritional intake and increasing physical activity. It will also include individual biweekly phone calls for 6 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CDC's PreventT2 Program with Added Sleep Content
Description: The CDC's PreventT2 program with added sleep content will involve 8 group sessions administered over 3 months. It is a behavioral intervention focused on achieving weight loss by improving sleep quality and nutritional intake and increasing sleep duration and physical activity. It will also include individual biweekly phone calls for 6 months.
Study: NCT03165760

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: protective ventilation
Description: the aim of the intervention is to ovoid Ventilator induced lung injury and inflammatory stress
Study: NCT04341831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teicoplanin
Description: We will be used 200mg Teicoplanin powder for each level of instrument.Hemovac drains will be used in either group. The drains will remain closed for 6 hours post-operatively for teicoplanin powder penetration in a surgical site.
Study: NCT00832442

Intervention type: DRUG
Intervention: Beta blocker
Description: as determined by individual study

Intervention type: OTHER
Intervention: Placebo
Description: in addition to usual care
Study: NCT01425970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Tablet, Oral, 25 mg, Once daily (QD), 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Tablet, Oral, 50 mg, Once daily (QD), 12 weeks
Study: NCT01554943

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cardiac MRI
Description: Patients will be submitted to extensive cardiac evaluation several years after completion of adjuvant chemotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiac MRI
Description: Patients will be submitted to extensive cardiac evaluation several years after completion of adjuvant chemotherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiac MRI
Description: Patients will be submitted to extensive cardiac evaluation several years after completion of adjuvant chemotherapy
Study: NCT03188900

Intervention type: BIOLOGICAL
Intervention: A collection of maternal plasma and serum
Description: A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP)

Intervention type: BIOLOGICAL
Intervention: A collection of maternal plasma and serum
Description: A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP)
Study: NCT01425970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Tablet, Oral, 50 mg, Once daily (QD), 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Tablet, Oral, 100 mg, Once daily (QD), 12 weeks
Study: NCT01478815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management
Description: Participants will receive the opportunity to win prizes for submitting cocaine negative urine samples.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care
Description: Standard Care
Study: NCT01425970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Tablet, Oral, 100 mg, Once daily (QD), 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Tablet, Oral, 100 mg, Once daily (QD), 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching with INX-08189
Description: Tablet, Oral, 0 mg, Once daily (QD), 12 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Description: Syringe, Subcutaneous injection, 180 μg, Once per week, 12 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Description: Syringe, Subcutaneous injection, 180 μg, Once per week, 12 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon alfa-2a
Description: Syringe, Subcutaneous injection, 180 μg, Once per week, 12 weeks

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated interferon alfa-2a
Description: Syringe, Subcutaneous injection, 180 μg, Once per week, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin
Description: Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Tablet, Oral, 200 mg, QD, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INX-08189
Description: Tablet, Oral, 200 mg, QD, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablet, Oral, 60 mg, QD, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablet, Oral, 60 mg, QD, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Tablet, Oral, 60 mg, QD, 12 weeks
Study: NCT03344575

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional defect closure
Description: Laparoscopic suturing of the defect prior to placing an intraperitoneal Onlay Mesh

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peritoneal bridging
Description: Laparoscopic closure of the defect by using a peritoneal flap prior to placing an intraperitoneal Onlay Mesh
Study: NCT02426749

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active repetitive Transcranial Magnetic Stimulation (rTMS)
Description: The treatments will be administered daily (five days/week) for two weeks, followed by three days on the third week (total of 13 treatments). Patients of both real and sham treatment groups will undergo rTMS treatment of 1.5-second duration trains of pulses at 20 Hz for a total of 25 trains with intertrain interval of 10 seconds applied to DLPFC bilaterally at 100% of the resting motor threshold. Thus, there will be a total of 1500 pulses per two sides of the brain per day, which is well within the safety limit of the rTMS application. During the intertrain intervals, the patients will be presented a series of objects and actions and asking to name them. The images will be projected on the wall in front of patient with duration of three seconds for each image. The aim is to keep the brain active while we stimulate it with rTMS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Sham rTMS is similar to Active rTMS but instead of a real coil, it uses a coil that attenuates the pulses such that no current will be induced in the brain.